Product Name :
Valrocemide
Description:
Valrocemide (TV1901) is a promising antiepileptic drug candidate that shows a broad spectrum of anticonvulsant activity.
CAS:
92262-58-3
Molecular Weight:
200.28
Formula:
C10H20N2O2
Chemical Name:
N-(carbamoylmethyl)-2-propylpentanamide
Smiles :
CCCC(CCC)C(=O)NCC(N)=O
InChiKey:
RALGCAOVRLYSMA-UHFFFAOYSA-N
InChi :
InChI=1S/C10H20N2O2/c1-3-5-8(6-4-2)10(14)12-7-9(11)13/h8H,3-7H2,1-2H3,(H2,11,13)(H,12,14)
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
Valrocemide (TV1901) is a promising antiepileptic drug candidate that shows a broad spectrum of anticonvulsant activity.|Product information|CAS Number: 92262-58-3|Molecular Weight: 200.28|Formula: C10H20N2O2|Chemical Name: N-(carbamoylmethyl)-2-propylpentanamide|Smiles: CCCC(CCC)C(=O)NCC(N)=O|InChiKey: RALGCAOVRLYSMA-UHFFFAOYSA-N|InChi: InChI=1S/C10H20N2O2/c1-3-5-8(6-4-2)10(14)12-7-9(11)13/h8H,3-7H2,1-2H3,(H2,11,13)(H,12,14)|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : ≥ 100 mg/mL (499.{{Irinotecan} medchemexpress|{Irinotecan} Autophagy|{Irinotecan} Purity & Documentation|{Irinotecan} In Vitro|{Irinotecan} manufacturer|{Irinotecan} Autophagy} 30 mM).{{Urolithin A} web|{Urolithin A} Immunology/Inflammation|{Urolithin A} Biological Activity|{Urolithin A} In Vitro|{Urolithin A} custom synthesis|{Urolithin A} Epigenetic Reader Domain} |Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.PMID:33036828 |Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vivo:|In mice, valrocemide affords complete protection against maximal electroshock-, pentylenetetrazole-, picrotoxin-, and bicuculline-induced seizures and 6-Hz “psychomotor” seizures with median effective dose (ED50) values of 151, 132, 275, 248, and 237 mg/kg, respectively. Valrocemide is also effective in preventing sound-induced seizures in Frings audiogenic-seizure susceptible mice (ED50, 52 mg/kg). The median neurotoxic dose in mice is 332 mg/kg. After oral administration to rats, valrocemide is active in the MES test, with an ED50 of 73 mg/kg, and the median neurotoxic dose is 1,000 mg/kg. Intraperitoneal administration of 300 mg/kg of valrocemide to hippocampal kindled Sprague–Dawley rats block generalized seizures and shorten the afterdischarge duration significantly. Valrocemide also provides complete protection from focal seizures in the corneally kindled rats (ED50, 161 mg/kg).|Products are for research use only. Not for human use.|
